Even when weight-related use is approved, many plans require prior authorization, documentation of previous weight-loss attempts, or specific lab results
Together, they promote fat loss while preserving lean muscle and improving overall metabolic wellness.
12 Pioglitazone is, however, associated with substantial side-effects, such as weight gain, fluid retention, heart failure and bone loss, so the American Association for the Study of Liver Diseases 2018 Guidelines state that pioglitazone may be used in biopsy-proven NASH patients after discussing the risks and benefits
In 2023, Eli Lilly entered the market with Zepbound (tirzepatide), boasting over 20% weight loss at 72 weeks and a slightly lower price